GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy

Adjuvant oxaliplatin-based chemotherapy is widely used for stage III colorectal cancer (CRC) after curative surgery. CRC is a molecularly heterogeneous disease, and our current knowledge of therapeutic response-related genetic factors remains limited. N-acetylgalactosaminyltransferase 14 (GALNT14)-r...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Wey-Ran, Chiang, Jy-Ming, Liang, Kung-Hao, Lim, Siew-Na, Lai, Ming-Wei, Tsou, Yung-Kuan, Hsieh, Tzu-Yun, Hsu, Chih-Kai, Yeh, Chau-Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
3500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998711/
https://www.ncbi.nlm.nih.gov/pubmed/27124048
http://dx.doi.org/10.1097/MD.0000000000003487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998711/
https://www.ncbi.nlm.nih.gov/pubmed/27124048
http://dx.doi.org/10.1097/MD.0000000000003487

Ejemplares similares